MARC details
| 000 -LEADER |
| fixed length control field |
03031cam a2200421 i 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
| control field |
20250918235656.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
| fixed length control field |
140716s2013 ne a 001 0 eng |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
| International Standard Book Number |
9780124071803 (pbk.) |
| Terms of availability |
RM146.67 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
| International Standard Book Number |
0124071805 (pbk.) |
| 039 #9 - LEVEL OF BIBLIOGRAPHIC CONTROL AND CODING DETAIL [OBSOLETE] |
| Level of rules in bibliographic description |
201509141151 |
| Level of effort used to assign nonsubject heading access points |
ruzini |
| Level of effort used to assign subject headings |
201504281125 |
| Level of effort used to assign classification |
zainol |
| y |
07-16-2014 |
| z |
fida |
| 040 ## - CATALOGING SOURCE |
| Modifying agency |
UKM |
| Description conventions |
rda |
| 090 ## - LOCALLY ASSIGNED LC-TYPE CALL NUMBER (OCLC); LOCAL CALL NUMBER (RLIN) |
| Classification number (OCLC) (R) ; Classification number, CALL (RLIN) (NR) |
QV745.B283f 2013 9 |
| 090 ## - LOCALLY ASSIGNED LC-TYPE CALL NUMBER (OCLC); LOCAL CALL NUMBER (RLIN) |
| Classification number (OCLC) (R) ; Classification number, CALL (RLIN) (NR) |
QV745 |
| Local cutter number (OCLC) ; Book number/undivided call number, CALL (RLIN) |
.B283f 2013 9 |
| 100 1# - MAIN ENTRY--PERSONAL NAME |
| Personal name |
Bartfai, Tamas, |
| Relator term |
author. |
| 245 14 - TITLE STATEMENT |
| Title |
The future of drug discovery : |
| Remainder of title |
who decides which diseases to treat? / |
| Statement of responsibility, etc. |
Tamas Bartfai, Professor and Director of the Harold L Dorris Neurological , Research Center, The Scripps Research Institute, La Jolla, CA, USA; Graham V. Lees, PhD, Corpus Alienum Oy, Helsinki, Finland. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
| Place of production, publication, distribution, manufacture |
London, UK : |
| Name of producer, publisher, distributor, manufacturer |
Academic Press, |
| Date of production, publication, distribution, manufacture, or copyright notice |
2013. |
| 264 ## - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
| Date of production, publication, distribution, manufacture, or copyright notice |
©2013 |
| 300 ## - PHYSICAL DESCRIPTION |
| Extent |
xxx, 346 pages : |
| Other physical details |
illustrations ; |
| Dimensions |
23 cm. |
| 336 ## - CONTENT TYPE |
| Content type term |
text |
| Source |
rdacontent |
| 337 ## - MEDIA TYPE |
| Media type term |
unmediated |
| Source |
rdamedia |
| 338 ## - CARRIER TYPE |
| Carrier type term |
volume |
| Source |
rdacarrier |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
| Bibliography, etc. note |
Includes bibliographical references. |
| 505 0# - FORMATTED CONTENTS NOTE |
| Formatted contents note |
Why there will be new drugs despite the ongoing'crisis' of drug development in big pharma --The need for medicines grows -- Medicines are becoming better: some of the breakthrough medicines of the past decades -- Which diseases do we want to treat? -- Therapeutic Areas: strategically important diseases for the future -- Blockbuster proprietary drugs versus generic drugs -- Why is pharma a special industry? -- Diagnosing towards personalized medicine -- Personalized medicine -- How much can drugs cost? --Modeling Drug Discovery until 2025 -- Drug development models between 2010 & 2025. |
| 520 ## - SUMMARY, ETC. |
| Summary, etc. |
'The Future of Drug Discovery: Who decides which diseases to treat? provides a timely and detailed look at the efforts of the pharmaceutical industry and how they relate, or should relate, to societal needs. The authors posit that as a result of increasing risk aversion and accelerated savings in research and development, the industry is not developing drugs for increasingly prevalent diseases, such as Alzheimer's disease, untreatable pain, antibiotics and more. This book carefully exposes the gap between the medicines and therapies we need and the current business path. By analyzing the situation and discussing prospects for the next decade, the The Future of Drug Discovery is a timely book for all those who care about the development needs for drugs for disease.' -- Publisher's website. |
| 650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM |
| Topical term or geographic name entry element |
Drug Discovery |
| General subdivision |
trends. |
| 650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM |
| Topical term or geographic name entry element |
Drug Industry |
| General subdivision |
economics. |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM |
| Topical term or geographic name entry element |
Drug development. |
| Source of heading or term |
fast |
| Authority record control number or standard number |
(OCoLC)fst00898670 |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM |
| Topical term or geographic name entry element |
Drugs |
| General subdivision |
Design. |
| Source of heading or term |
fast |
| Authority record control number or standard number |
(OCoLC)fst00898790 |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
| Personal name |
Lees, Graham V., |
| Relator term |
author. |
| 907 ## - LOCAL DATA ELEMENT G, LDG (RLIN) |
| a |
.b15952538 |
| b |
2019-11-12 |
| c |
2019-11-12 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
| Koha item type |
AM |
| Suppress in OPAC |
No |
| Call number prefix |
QV745.B283f 2013 9 |
| 914 ## - VTLS Number |
| VTLS Number |
vtls003565152 |
| 990 ## - EQUIVALENCES OR CROSS-REFERENCES [LOCAL, CANADA] |
| Link information for 9XX fields |
zr |
| 991 ## - LOCAL NOTE (NAMA FAKULTI/INSTITUT/PUSAT) |
| a |
Fakulti Farmasi, KKL |
| 998 ## - LOCAL CONTROL INFORMATION (RLIN) |
| Library |
PERPUSTAKAAN DR ABDUL LATIFF |
| Operator's initials, OID (RLIN) |
2014-03-07 |
| Cataloger's initials, CIN (RLIN) |
m |
| Material Type (Sierra) |
Printed Books |
| Language |
English |
| Country |
|
| -- |
0 |
| -- |
.b15952538 |